基孔肯雅热病毒疫苗在美国维尔京群岛的可接受性。
Acceptability of a Chikungunya Virus Vaccine, United States Virgin Islands.
机构信息
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
Am J Trop Med Hyg. 2022 Dec 26;108(2):363-365. doi: 10.4269/ajtmh.22-0429. Print 2023 Feb 1.
Chikungunya virus, a mosquito-borne alphavirus, causes acute febrile illness with polyarthralgia. Groups at risk for severe disease include neonates, people with underlying medical conditions, and those aged ≥ 65 years. Several chikungunya vaccines are in late clinical development with licensure expected in the United States during 2023. We administered a questionnaire to randomly selected households in the U.S. Virgin Islands (USVI) to assess interest in a hypothetical chikungunya vaccine. Estimates were calibrated to age and sex of USVI population, and univariate and multivariable analyses were performed. Of 966 participants, 520 (adjusted 56%, 95% CI = 51-60%) were interested in receiving the vaccine. Of 446 participants not interested in vaccination, 203 (adjusted 47%, 95% CI = 41-52%) cited safety concerns as the reason. Educational efforts addressing vaccine safety concerns and risk factors for severe disease would likely improve vaccine acceptability and uptake among those most at risk.
基孔肯雅热病毒是一种蚊媒甲病毒，可引起伴有多关节痛的急性发热疾病。易患严重疾病的人群包括新生儿、有基础疾病的人群以及年龄≥65 岁的人群。几种基孔肯雅热疫苗正在进行后期临床开发，预计 2023 年在美国获得许可。我们向美属维尔京群岛（USVI）的随机家庭发放了一份问卷，以评估对假设的基孔肯雅热疫苗的兴趣。估计数根据 USVI 人口的年龄和性别进行了校准，并进行了单变量和多变量分析。在 966 名参与者中，有 520 名（调整后 56%，95%CI=51-60%）表示有兴趣接种疫苗。在 446 名对疫苗接种不感兴趣的参与者中，有 203 名（调整后 47%，95%CI=41-52%）表示安全问题是他们拒绝接种的原因。开展疫苗安全性问题和严重疾病风险因素的教育工作，可能会提高那些最易受感染人群的疫苗可接受性和接种率。
Zotero 插件